RxSight, Inc. (RXST)
NASDAQ: RXST · IEX Real-Time Price · USD
60.65
-1.61 (-2.59%)
At close: May 17, 2024, 4:00 PM
60.18
-0.47 (-0.77%)
After-hours: May 17, 2024, 5:02 PM EDT
RxSight Revenue
RxSight had revenue of $101.10M in the twelve months ending March 31, 2024, with 75.67% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $29.51M with 68.75% year-over-year growth. In the year 2023, RxSight had annual revenue of $89.08M with 81.77% growth.
Revenue (ttm)
$101.10M
Revenue Growth
+75.67%
P/S Ratio
23.38
Revenue / Employee
$270,324
Employees
374
Market Cap
2.36B USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 89.08M | 40.07M | 81.77% |
| Dec 31, 2022 | 49.01M | 26.41M | 116.90% |
| Dec 31, 2021 | 22.59M | 7.92M | 53.92% |
| Dec 31, 2020 | 14.68M | 12.44M | 554.98% |
| Dec 31, 2019 | 2.24M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Patterson Companies | 6.57B |
| agilon health | 4.78B |
| Fortrea Holdings | 3.11B |
| Indivior | 1.12B |
| ACADIA Pharmaceuticals | 813.81M |
| NovoCure | 525.66M |
| Vericel | 207.78M |
| Rhythm Pharmaceuticals | 91.93M |
RXST News
- 5 days ago - RxSight, Inc. Announces Closing of its Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 9 days ago - RxSight, Inc. Announces Pricing of Public Offering of Common Stock - GlobeNewsWire
- 12 days ago - RxSight, Inc. Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 26 days ago - RxSight, Inc. to Report First Quarter Financial Results on May 6, 2024 - GlobeNewsWire
- 6 weeks ago - RxSight Announces Commercial Launch of its Newest Light Adjustable Lens™, the LAL+™, and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual Meeting - GlobeNewsWire
- 7 weeks ago - RxSight, Inc. to Participate in the 23rd Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 2 months ago - RxSight, Inc. to Participate in the 34th Annual Oppenheimer Healthcare Conference - GlobeNewsWire
- 2 months ago - RxSight, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire